Allergic adverse events · patients with Helicobacter pylori infection
It is very uncertain whether any antibiotic regimen plus N‐acetylcysteine changes allergic adverse events compared with the same regimen without N‐acetylcysteine (with or without placebo) (very low certainty).
1 finding from 1 review
Adverse events ‐ toxic reaction (short term) · patients with Helicobacter pylori infection
1 finding from 1 review
Anxiety · people with inflammatory bowel disease
2 findings from 1 review
Depression at 12 weeks · people with inflammatory bowel disease
1 finding from 1 review
Depression at 12 months · people with inflammatory bowel disease
1 finding from 1 review
Adverse events at 12 months · people with inflammatory bowel disease
Antidepressants showed no clear difference in adverse events at 12 months compared with placebo (low certainty).
1 finding from 1 review
Quality of life · people with inflammatory bowel disease
1 finding from 1 review
Pain · people with inflammatory bowel disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Maintenance of remission · people with inflammatory bowel disease
Antidepressants showed no clear difference in maintenance of remission at 12 months compared with placebo (low certainty).
1 finding from 1 review
Endoscopic relapse · people with inflammatory bowel disease
It is very uncertain whether antidepressants changes endoscopic relapse at 12 months compared with placebo (very low certainty).
1 finding from 1 review
Quality of life, measured by CRQ (dyspnoea, fatigue, emotional function, and mastery subscales) · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Macrolide showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found